Please try another search
By Danilo Masoni MILAN (Reuters) - Investors have been lukewarm about the earnings of some of Europe's star performers, which suggests more neglected corners of the market are popping up on their...
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment,...
By Ankika Biswas and Johann M Cherian (Reuters) -European shares fell slightly in their first May trading session on Thursday as investors returned from a mid-week holiday to gauge a slew of earnings...
By Ludwig Burger (Reuters) - Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial...
LONDON (Reuters) - Novo Nordisk (CSE:NOVOb) has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have...
By Martin Coulter LONDON (Reuters) -Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk (CSE:NOVOb), said on Wednesday it planned to invest around $200 million in...
(Reuters) -Most doses of Eli Lilly (NYSE:LLY)'s diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review